Clinical Analysis of Gene Mutation and Vascular Events in Patients with BCR/ABL Negative Myeloproliferative Neoplasms.
10.19746/j.cnki.issn.1009-2137.2022.03.024
- Author:
Bao-Dan HU
1
;
Lin CHEN
2
Author Information
1. The Second College of Clinical Medicine of Chongqing Medical University, Chongqing 400010, China.
2. Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China,E-mail: chen2018lin2018@163.com.
- Publication Type:Journal Article
- Keywords:
coagulation function;
hemorrhagic events;
myeloproliferative neoplasm;
peripheral blood cell count;
thrombotic events
- MeSH:
Hemoglobins/genetics*;
Hemorrhage;
Humans;
Janus Kinase 2/genetics*;
Male;
Mutation;
Myeloproliferative Disorders/genetics*;
Polycythemia Vera/genetics*;
Retrospective Studies;
Thrombocythemia, Essential;
Thrombosis
- From:
Journal of Experimental Hematology
2022;30(3):813-818
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the relationship between clinical features, peripheral blood cell count, coagulation function, gene mutation and hemorrhagic events and thrombotic events in essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis(PMF) patients.
METHODS:Clinical data of 78 patients with ET, PV, and PMF who were admitted to the Second Affiliated Hospital of Chongqing Medical University between September 2019 and August 2020 were retrospectively analyzed. Information about sex, age, gene mutation, peripheral blood cell count, coagulation function, and hemorrhagic and thrombotic events was included, and the influence of these data on the occurrence of hemorrhagic and thrombotic events was estimated.
RESULTS:Among the 78 patients with myeloproliferative neoplasms, there were 47 cases of ET, 15 cases of PV, and 16 cases of PMF.A total of 10 patients (12.82%) experienced hemorrhagic events and 27 (34.62%) experienced thrombotic events. Male,patients aged ≥ 60 years, and patients with a JAK2V617F mutation were more likely to experience thrombotic events (P<0.05). Patients with thrombotic events had higher platelet (PLT) counts and fibrinogen (FIB) levels than patients without hemorrhagic-thrombotic events (P<0.05).White blood cell (WBC) count, red blood cell (RBC) count, hemoglobin (HGB) level, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and international normalized ratio (INR) showed no statistical difference between patients with thrombotic events and patients without hemorrhagic-thrombotic events (P>0.05). There was also no significant difference in the above-mentioned indexes between patients with hemorrhagic events and patients without hemorrhagic-thrombotic events (P>0.05). Among JAK2V617F positive myeloproliferative neoplasm patients, male patients were more likely to have thrombotic events (P<0.05), and patients with thrombotic events had higher platelet counts than those without hemorrhagic-thrombotic events (P<0.05). There was no significant difference in age, white blood cell count, red blood cell count, hemoglobin level, PT, APTT, FIB, TT or INR between patients with thrombotic events and patients without hemorrhagic-thrombotic events (P>0.05).
CONCLUSION:Sex, age, JAK2V617F mutation and platelet count have a certain value for predicting thrombosis in patients with myeloproliferative neoplasms.
